Your browser doesn't support javascript.
COVID19-associated new-onset movement disorders: a follow-up study.
Schneider, Susanne A; Desai, Soaham; Phokaewvarangkul, Onanong; Rosca, Elena Cecilia; Sringean, Jirada; Anand, Pria; Bravo, Gary Álvarez; Cardoso, Francisco; Cervantes-Arslanian, Anna M; Chovatiya, Harshad; Crosiers, David; Dijkstra, Femke; Fearon, Conor; Grandas, Francisco; Guedj, Eric; Méndez-Guerrero, Antonio; Hassan, Muhammad; Jankovic, Joseph; Lang, Anthony E; Makhoul, Karim; Muccioli, Lorenzo; O'Shea, Sarah A; Ostovan, Vahid Reza; Perez-Sanchez, Javier Ricardo; Ramdhani, Ritesh; Ros-Castelló, Victoria; Schulte, Christina; Shah, Priyank; Wojtecki, Lars; Pal, Pramod Kumar.
  • Schneider SA; Department of Neurology, Ludwig Maximilians University Munich, Marchioninistr. 15, 81377, Munich, Germany. susanne.schneider@med.uni-muenchen.de.
  • Desai S; Department of Neurology, Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University, Karamsad, Anand, Gujarat, India.
  • Phokaewvarangkul O; Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama 4 Road, Bangkok, Thailand.
  • Rosca EC; Department of Neurology, Victor Babes University of Medicine and Pharmacy, Timisoara, Romania.
  • Sringean J; Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, 1873 Rama 4 Road, Bangkok, Thailand.
  • Anand P; Departments of Neurology, Neurosurgery, and Medicine Boston University School of Medicine and Boston Medical Center, Boston, USA.
  • Bravo GÁ; Neuroimmunology and Multiple Sclerosis Unit of Girona, University Hospital Dr. Josep Trueta of Girona, Girona, Catalonia, Spain.
  • Cardoso F; Movement Disorders Unit, Neurology Service, Internal Medicine Department, UFMG, Belo Horizonte, Brazil.
  • Cervantes-Arslanian AM; Departments of Neurology, Neurosurgery, and Medicine Boston University School of Medicine and Boston Medical Center, Boston, USA.
  • Chovatiya H; Department of Neurology, Shree Krishna Hospital, Pramukhswami Medical College, Bhaikaka University, Karamsad, Anand, Gujarat, India.
  • Crosiers D; Faculty of Medicine and Health Sciences, Translational Neurosciences, University of Antwerp, Antwerp, Belgium.
  • Dijkstra F; Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.
  • Fearon C; Faculty of Medicine and Health Sciences, Translational Neurosciences, University of Antwerp, Antwerp, Belgium.
  • Grandas F; Department of Neurology, Antwerp University Hospital, Antwerp, Belgium.
  • Guedj E; Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital - UHN, University of Toronto, Toronto, ON, Canada.
  • Méndez-Guerrero A; Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Hassan M; Institut Fresnel, Nuclear Medicine Department, Aix Marseille Univ, APHM, CNRS, Centrale Marseille, Timone Hospital, CERIMED, Marseille, France.
  • Jankovic J; Neurology Department, Hospital 12 de Octubre, Madrid, Spain.
  • Lang AE; Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.
  • Makhoul K; Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Muccioli L; Division of Neurology, Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital - UHN, University of Toronto, Toronto, ON, Canada.
  • O'Shea SA; Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.
  • Ostovan VR; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • Perez-Sanchez JR; Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, USA.
  • Ramdhani R; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Ros-Castelló V; Movement Disorders Unit, Neurology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Schulte C; Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
  • Shah P; Neurology Department, Ramon y Cajal University Hospital, Madrid, Spain.
  • Wojtecki L; Departmemt of Neurology and Neurorehabilitation, Hospital Zum Heiligen Geist, Academic Teaching Hospital of the Heinrich-Heine-University Duesseldorf, Kempen, Germany.
  • Pal PK; Privya Neurology Clinic, Ahmedabad, Gujarat, India.
J Neurol ; 270(5): 2409-2415, 2023 May.
Article in English | MEDLINE | ID: covidwho-2280196
ABSTRACT

BACKGROUND:

Neurological symptoms are common manifestation in acute COVID-19. This includes hyper- and hypokinetic movement disorders. Data on their outcome, however, is limited.

METHODS:

Cases with new-onset COVID-19-associated movement disorders were identified by searching the literature. Authors were contacted for outcome data which were reviewed and analyzed.

RESULTS:

Movement disorders began 12.6 days on average after the initial onset of COVID-19. 92% of patients required hospital admission (mean duration 23 days). In a fraction of patients (6 of 27; 22%; 4 males/2 females, mean age 66.8 years) the movement disorder (ataxia, myoclonus, tremor, parkinsonism) was still present after a follow-up period of 7.5 ± 3 weeks. Severe COVID-19 in general and development of encephalopathy were risk factors, albeit not strong predictors, for the persistence.

CONCLUSIONS:

The prognosis of new-onset COVID-19-associated movement disorder appears to be generally good. The majority recovered without residual symptoms within several weeks or months. Permanent cases may be due to unmasking of a previous subclinical movement disorder or due to vascular/demyelinating damage. Given the relatively low response rate of one third only and the heterogeneity of mechanisms firm conclusions on the (long-term) outome cannot, however, be drawn.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Movement Disorders Type of study: Cohort study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male Language: English Journal: J Neurol Year: 2023 Document Type: Article Affiliation country: S00415-023-11661-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Movement Disorders Type of study: Cohort study / Prognostic study Topics: Long Covid Limits: Aged / Female / Humans / Male Language: English Journal: J Neurol Year: 2023 Document Type: Article Affiliation country: S00415-023-11661-x